Table 1.
Clinicopathological characteristics of the patients grouped by KLF5 Expression.
| Total | KLF5 Expression (Low) |
KLF5 Expression (High) |
P | |
|---|---|---|---|---|
| Cases | 74 | 24 | 50 | |
| Sex | 0.296 | |||
| Male | 55 (74.3%) | 16 (66.7%) | 39 (78.0%) | |
| Female | 19 (25.7%) | 8 (33.3%) | 11 (22.0%) | |
| Age (year) | 0.909 | |||
| ≤55 | 24 (32.4%) | 8 (33.3%) | 16 (32.0%) | |
| >55 | 50 (67.6%) | 16 (66.7%) | 34 (68.0%) | |
| Length (cm) | 0.008 ** | |||
| ≤5 | 39 (52.7%) | 18 (75.0%) | 21 (42.0%) | |
| >5 | 35 (47.3%) | 6 (25.0%) | 29 (58.0%) | |
| Serosa Invasion | 0.054 | |||
| Negative | 58 (78.4%) | 22 (91.7%) | 36 (72.0%) | |
| Positive | 16 (21.6%) | 2 (8.3%) | 14 (28.0%) | |
| Primary Tumor (T) | 0.029 * | |||
| T1/T2 | 19 (25.7%) | 10 (41.7%) | 9 (18.0%) | |
| T3/T4 | 55 (74.3%) | 14 (58.3%) | 41 (82.0%) | |
| Regional Lymph Nodes (N) | 0.619 | |||
| N0/N1 | 37 (50.0%) | 13 (54.2%) | 24 (48.0%) | |
| N2/N3 | 37 (50.0%) | 11 (45.8%) | 26 (52.0%) | |
| Distant Metastasis (M) | 0.329 | |||
| M0 | 60 (81.1%) | 21 (87.5%) | 39 (78.0%) | |
| M1 | 14 (18.9%) | 3 (12.5%) | 11 (22.0%) | |
| TNM | 0.189 | |||
| Ⅰ/Ⅱ | 32 (43.2%) | 13 (54.2%) | 19 (38.0%) | |
| Ⅲ/Ⅳ | 42 (56.8%) | 11 (45.8%) | 31 (62.0%) | |
| Histological Grade (G) | 0.762 | |||
| Well/Moderate | 29 (39.2%) | 10 (41.7%) | 19 (38.0%) | |
| Poor/Undifferentiated | 45 (60.8%) | 14 (58.3%) | 31 (62.0%) | |
* p < 0.05, ** p < 0.01 (chi-square test). The T stage refers to the extent of the primary tumor; the N stage refers to the number of lymph nodes with metastatic cancer; the M stage refers to distant metastasis. Tumors were staged according to the AJCC TNM staging system (7th edition).